Source: Υπουργείο Υγείας (CY) Revision Year: 2022 Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Medocef 1g powder for solution for injection or infusion.
Medocef 2g powder for solution for injection or infusion.
| Pharmaceutical Form |
|---|
|
White or slightly yellow, hygroscopic powder. Powder for solution for injection or infusion. |
Each vial contains Cefoperazone 1g or 2g as Cefoperazone sodium.
Excipient with known effect: sodium.
Each 1g vial contains 34.4 mg sodium.
Each 2g vial contains 68.8 mg sodium.
| Active Ingredient | Description | |
|---|---|---|
| Cefoperazone |
Cefoperazone, a third-generation cephalosporin, interferes with cell wall synthesis by binding to the penicillin-binding proteins (PBPs), thus preventing cross-linking of nascent peptidoglycan. Cefoperazone is stable to penicillinases and has a high degree of stability to many beta-lactamases produced by gram-negative bacteria. |
| List of Excipients |
|---|
|
None. |
Colourless moulded type I glass vials of 20ml capacity, sealed with a rubber stopper and aluminium overcap. Each vial contains either 1g or 2g of cefoperazone as cefoperazone sodium.
Cartons of 1, 10 or 25, 50 and 100 vials are available.
Not all pack sizes may be marketed.
MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Medocef 1g: 12622
Medocef 2g: 12621
Date of first authorization
Medocef 1g: 29/01/1990
Medocef 2g: 29/01/1990
Renewal of Authorization:
Medocef 1g: 17/10/2011
Medocef 2g: 17/10/2011
| Drug | Countries | |
|---|---|---|
| MEDOCEF | Cyprus, Romania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
